Other conditions Board decisions

The Board denied service connection for the cause of the Veteran's death, finding that his fatal conditions were not related to his military service or exposure to herbicides.

The Veteran's claim for service connection for residuals of a pineal cyst of the brain is remanded due to insufficient examination and lack of clear opinion regarding whether her condition was aggravated by service or if it began in service.

The Board found that the Appellant was insane at the time of his misconduct, which lifted the regulatory bar to VA benefits.

The Board denied the Veteran's claim for service connection for residuals of mandible surgery, finding that the numbness was a known complication of the surgery and not a resultant disability from an in-service event.

The Board denied the Veteran's claim for service connection as his spheno cavernous sinus meningioma did not manifest in service and is not otherwise related to his active service.

The Veteran's status post right salpingo-oophorectomy for serous cystadenoma and her pelvic inflammatory disease are granted service connection. Additional development is needed to determine the relationship of other gynecological conditions.

The Veteran's appeal for a clothing allowance based on the use of his right knee brace was dismissed as he withdrew the appeal in writing.

The Veteran's herpes simplex requires constant or near-constant systemic therapy, and the Board has granted a rating of 60 percent for this condition. The case is remanded for further consideration regarding TDIU.

The Veteran's varicose veins of the right and left lower extremities are currently rated at 10% prior to December 29, 2014 and in excess of 20% thereafter. The Board found no evidence supporting a higher rating based on persistent edema or ulceration.

The Board has dismissed all issues on appeal due to the Veteran's representative explicitly withdrawing the appeal in December 2021.

The Board has determined that the Veteran's bladder disability is related to his active-duty service and grants the claim for service connection.

The Board denied the Veteran's claim for compensation under 38 U.S.C. § 1151 as there is no evidence that her right upper quadrant pain was caused by or worsened by VA treatment, and she did not have a qualifying additional disability.

The Board dismissed the appeal because the appellant requested to withdraw it before a decision was made.

The Board has determined that the Veteran's claim is not complete due to missing documents and needs further clarification on whether his business was economically viable in 2014. The AOJ must provide a supplemental statement of the case with this information.

The Veteran's skin disability, diagnosed as rash, dermatitis, and xerosis, is found to have begun during service and has been continuous since then. The Board granted service connection for the skin disability.

The Board has remanded the claim of TDIU due to a lack of a Supplemental Statement of the Case (SSOC) discussing this issue after assigning a rating for insomnia. The SSOC should be issued.

The Board has remanded the case due to insufficient medical opinions regarding service connection for collagenous colitis, including as secondary to service-connected disabilities. The Veteran's claim will be reviewed with an addendum opinion from a gastroenterologist.

The Board has determined that additional examinations and development are needed for the Veteran's claims of entitlement to a separate, compensable disability rating for right eye visual impairment associated with type II diabetes mellitus; service connection for sleep apnea as secondary to type II diabetes mellitus; and service connection for hypertension as secondary to type II diabetes mellitus.

The Veteran's gout of the right hand was granted a 40 percent evaluation prior to March 29, 2018. From that date onwards, his evaluations for individual fingers were denied.

The Board granted a 30 percent rating for the residuals of a left foot bunionectomy, including flat foot, hammer toes, and hallux valgus, effective from August 2017.